• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

    11/14/24 3:33:13 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RIGL alert in real time by email
    SC 13G/A 1 ea0221047-13ga2soleus_rigel.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    RIGEL PHARMACEUTICALS, INC.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    766559702

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP NO. 766559702

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Master Fund, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    934,788 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    934,788 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    934,788 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.3% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    FI

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital Management is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus Capital Group, LLC and of Soleus GP, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, as amended (the “Exchange Act”), and the filing of this report shall not be deemed an admission that any of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC or Mr. Levy is the beneficial owner of such shares for any other purpose.

     

    (2) This percentage is calculated based upon 17,615,040 shares of the common stock of Rigel Pharmaceuticals, Inc. (the “Issuer”) outstanding as of November 4, 2024, as reported on the cover of the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2024 filed with the Securities and Exchange Commission on November 7, 2024 (the “Form 10-Q”).

     

    2

     

     

    CUSIP NO. 766559702

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    934,788 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    934,788 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    934,788 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.3% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital Management is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus Capital Group, LLC and of Soleus GP, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC or Mr. Levy is the beneficial owner of such shares for any other purpose.

     

    (2) This percentage is calculated based upon 17,615,040 shares of common stock of the Issuer outstanding as of November 4, 2024, as set forth on the cover of the Form 10-Q.

     

    3

     

     

    CUSIP NO. 766559702

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Group, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    934,788 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    934,788 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    934,788 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.3% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital Management is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus Capital Group, LLC and of Soleus GP, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC or Mr. Levy is the beneficial owner of such shares for any other purpose.

     

    (2) This percentage is calculated based upon 17,615,040 shares of common stock of the Issuer outstanding as of November 4, 2024, as set forth on the cover of the Form 10-Q.

     

    4

     

     

    CUSIP NO. 766559702

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Management, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    934,788 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    934,788 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    934,788 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.3% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital Management is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus Capital Group, LLC and of Soleus GP, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC or Mr. Levy is the beneficial owner of such shares for any other purpose.

     

    (2) This percentage is calculated based upon 17,615,040 shares of common stock of the Issuer outstanding as of November 4, 2024, as set forth on the cover of the Form 10-Q.

     

    5

     

     

    CUSIP NO. 766559702

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus GP, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    934,788 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    934,788 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    934,788 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.3% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital Management is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus Capital Group, LLC and of Soleus GP, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC or Mr. Levy is the beneficial owner of such shares for any other purpose.

     

    (2) This percentage is calculated based upon 17,615,040 shares of common stock of the Issuer outstanding as of November 4, 2024, as set forth on the cover of the Form 10-Q.

     

    6

     

     

    CUSIP NO. 766559702

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Guy Levy

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    934,788 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    934,788 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    934,788 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.3% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital Management is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus Capital Group, LLC and of Soleus GP, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC or Mr. Levy is the beneficial owner of such shares for any other purpose.

     

    (2) This percentage is calculated based upon 17,615,040 shares of common stock of the Issuer outstanding as of November 4, 2024, as set forth on the cover of the Form 10-Q.

     

    7

     

     

    Item 1.

     

      (a) Name of Issuer

     

    Rigel Pharmaceuticals, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

     

    611 Gateway Boulevard, Suite 900

    South San Francisco, CA

     

    Item 2.

     

      (a) Name of Person(s) Filing

     

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Soleus Capital Management, L.P.

    Soleus GP, LLC

    Guy Levy

     

      (b) Address of Principal Business Office or, if none, Residence

     

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Management, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus GP, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Guy Levy

    c/o Soleus Capital Management, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    8

     

     

      (c) Citizenship

     

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC – Delaware

    Soleus Capital Management, L.P. – Delaware

    Soleus GP, LLC – Delaware

    Guy Levy – United States

     

      (d) Title of Class of Securities

     

    Common Stock, $0.001 par value per share

     

      (e) CUSIP Number

     

    766559702

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).
         
    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
         
    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
         
    (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership.

     

    The information required by this item with respect to reach reporting person is set forth in rows 5 – 11 on the cover pages to this Schedule 13G.

     

    As noted on the cover pages of this Schedule 13G, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital LLC is the sole general partner of Master Fund, Soleus Capital Management is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. As the sole managing member of each of Soleus Capital Group, LLC and of Soleus GP, LLC, Mr. Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the securities held directly by Master Fund.

     

    Each of Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, Soleus GP, LLC or Mr. Levy is the beneficial owner of such shares for any other purpose.

     

    9

     

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    10

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024 Soleus Capital Master Fund, L.P.
       
      By: Soleus Capital, LLC, its General Partner
       
      By: Soleus Capital Group, LLC, its Managing Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Capital, LLC
       
      By: Soleus Capital Group, LLC, its Managing Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Capital Group, LLC
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Capital Management, L.P.
       
      By:  Soleus GP, LLC, its General Partner
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus GP, LLC
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 /s/ Guy Levy
      Name: Guy Levy

     

    Footnotes:

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    11

     

     

    EXHIBIT 99.A

     

    EXHIBIT A

    JOINT FILING AGREEMENT

     

    Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, Soleus Capital Management, L.P., a Delaware limited partnership, Soleus GP, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934, as amended.

     

    It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other party unless such party knows or has reason to believe that such information is inaccurate.

     

    It is understood and agreed that a copy of this Agreement shall be attached as an exhibit to the statement on Schedule 13G, and any amendments hereto, filed on behalf of each of the parties hereto.

     

    Date: November 14, 2024 Soleus Capital Master Fund, L.P.
       
      By: Soleus Capital, LLC, its General Partner
       
      By: Soleus Capital Group, LLC, its Managing Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Capital, LLC
       
      By: Soleus Capital Group, LLC, its Managing Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Capital Group, LLC
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Capital Management, L.P.
       
      By: Soleus GP, LLC, its General Partner
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title:   Managing Member
       
    Date: November 14, 2024 Soleus GP, LLC
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title:   Managing Member
       
    Date: November 14, 2024 /s/ Guy Levy
      Name: Guy Levy

     

     

     

     

    Get the next $RIGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RIGL

    DatePrice TargetRatingAnalyst
    4/3/2023$2.00Neutral
    Piper Sandler
    6/9/2022Buy → Neutral
    Citigroup
    6/8/2022$7.00 → $1.00Overweight → Neutral
    Piper Sandler
    6/8/2022$6.00 → $1.00Overweight → Neutral
    Cantor Fitzgerald
    3/23/2022$4.00Neutral
    B. Riley Securities
    More analyst ratings

    $RIGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

      First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on

      5/6/25 4:01:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

      SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's webs

      4/29/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (NASDAQ:RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 23,350 stock options and restricted stock units to seven non-executive employees vesting over four years with a one-year cliff.   About RigelRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotechnology company dedicated to discovering, developing a

      4/4/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Rigel Pharma with a new price target

      Piper Sandler resumed coverage of Rigel Pharma with a rating of Neutral and set a new price target of $2.00

      4/3/23 9:11:21 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharma downgraded by Citigroup

      Citigroup downgraded Rigel Pharma from Buy to Neutral

      6/9/22 7:22:28 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Rigel Pharma from Overweight to Neutral and set a new price target of $1.00 from $7.00 previously

      6/8/22 1:49:43 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    SEC Filings

    See more
    • Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

      5/6/25 4:23:43 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rigel Pharmaceuticals Inc.

      10-Q - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

      5/6/25 4:05:42 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Rigel Pharmaceuticals Inc.

      SCHEDULE 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      4/17/25 9:35:38 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

      SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      11/14/24 5:18:08 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

      SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      11/14/24 3:33:13 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rigel Pharmaceuticals Inc.

      SC 13G - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      11/8/24 9:33:38 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Financials

    Live finance-specific insights

    See more
    • Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

      First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on

      5/6/25 4:01:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

      SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's webs

      4/29/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million 2024 total revenue of approximately $179.3 million, which includes TAVALISSE® net product sales of $104.8 million, REZLIDHIA® net product sales of $23.0 million and GAVRETO® net product sales of $17.1 millionR289 granted Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS and Orphan Drug designation for the treatment of MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast sch

      3/4/25 4:01:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP & Chief Financial Officer Schorno Dean L

      4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

      3/19/25 8:56:36 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, Chief Commercial Officer Santos David A

      4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

      3/19/25 8:56:27 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, Chief Medical Officer Rojkjaer Lisa

      4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

      3/19/25 8:56:18 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

      SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertise in clinical drug development and translational research, and portfolio strategy.   "We are pleased to have Mark join our Board," said Raul Rodriguez, Rigel's president and CEO. "His experience in clinical development, translational research and portfolio strategy will be a valuable addition to Rigel as we advance our hematology and oncology developm

      3/10/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background. "It is a pleasure to welcome Lisa to the team. She brings to Rigel a strong combination of industry leadership experience paired with drug development and regulatory affairs expertise. Her robust hematology and oncology knowledge comp

      3/12/24 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

      STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position

      9/12/22 7:00:00 AM ET
      $CARA
      $IOVA
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)